Besides, mutations in carcinogenic pathways, such as the RTK–MAPK and PI3K–MTOR pathways, have been revealed to be helpful as therapeutic targets in bladder cancer by the Cancer Genome Atlas (TCGA) project (71, 72). The gene discussed is MTOR; the disease is urinary bladder carcinoma.